Xiaoran Ma

Xiaoran Ma

Auto-generated profile, based on publicly available information

Xiaoran Ma

Tianjin University

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2024 in Journal of Global Health
Verified
Journal Article
Open access
SZSan Zhu
San Zhu
WWWenjing Wang
Wenjing Wang
JHJiaze He
Jiaze He
WDWenshan Duan
Wenshan Duan
XMXiaoran Ma
Xiaoran Ma
XHXiaojie Huang
Xiaojie Huang
The widespread use of antiretroviral therapy (ART) has risen the life expectancy of patients with AIDS [1]. Simultaneously, the number of elderly people living with HIV (PLWH) is rising and expected to continue. The proportion of PLWH worldwide aged ≥50 years or was expected to increase from 21% at the end of 2019 to 73% […]

8 January 2025 in Emerging Microbes & Infections
Verified
Journal Article
Open access
SZShengnan Zhao
Shengnan Zhao
WWWenjing Wang
Wenjing Wang
SLSibo Li
Sibo Li
JHJiaze He
Jiaze He
WDWenshan Duan
Wenshan Duan
XHXiaojie Huang
Xiaojie Huang
Low-level viraemia (LLV) following antiretroviral therapy (ART) in people living with HIV (PLWH) has not received sufficient attention. To the determine the prevalence of LLV and its association with virological failure (VF), we systematically reviewed evidence-based interventions for PLWH. We searched PubMed, the Cochrane Library, Embase, and Web of Science from inception to 22 May 2024. Cohorts with samples sizes smaller than 1000 in size were excluded. Data from 16 cohort studies, encompassing 1,349,306 PLWH, revealed a pooled prevalence of LLV of 13.81%. Relative risk (RR) and 95% confidence intervals (CI) identified the following risk factors for LLV: viral load (VL) ≥ 105 copies/mL at baseline (1.79, 1.11-2.88), AIDS-defined illness at baseline (1.24, 1.10-1.40), and protease inhibitor-based regimen at ART initiation (1.53, 1.45-1.62) are the risk factors for LLV. Conversely, CD4 count ≥200 cells/μL at baseline (0.90, 0.82-0.98), non-nucleoside reverse transcriptase inhibitor-based regimen (0.81, 0.68-0.96) and the integrase strand transfer inhibitor (INSTI)-based regimen (0.60, 0.42-0.85) were associated with a reduced risk of LLV. Pooling the adjusted hazard ratio (aHR) and the 95% CI, we found that LLV increased the risk of VF with rising VL among 96,711 PLWH (aHR 2.77, 95% CI 2.03-3.76) and increased the risk of all-cause mortality at high VL levels among 14,229 PLWH (aHR 1.66, 95% CI 1.16-2.37). Therefore, the prevalence of LLV in PLWH should not be overlooked. This study aims to guide better management strategies to improve clinical outcomes in patients with LLV.

17 August 2023
Verified
Conference Paper
Closed access
PDF file
YLYachao Li
Yachao Li
Haiying SongHaiying Song
Haiying Song
XMXiaoran Ma
Xiaoran Ma
CGChao Ge
Chao Ge
Shi-Bing LiuShi-Bing Liu
Shi-Bing Liu
The ineffectiveness of powder morphology of crystal materials for laser polarization has reached a consensus in almost all steady-state experiments. However, in-depth understanding about their anisotropic behavior in ultrafast carrier dynamics is still lacking. Here we systematically explore the polarization response of MAPbI3 powder to ultrafast laser based on two-color pump-probe transmission technology. The isotropy of pump polarization and the anisotropy of probe polarization reveal the related mechanism of the interaction between ultrafast laser polarization and powder materials. It provides insight into the ultrafast photophysical process of MAPbI3 powder and helps to develop polarization-sensitive and ultrafast-responsive optoelectronic devices.